79 results
Page 2 of 4
424B3
bb6gdgpmaj9fxf kvy
9 Aug 22
Prospectus supplement
9:26am
8-K
EX-99.1
trdgi4rnel p52
12 Jul 22
Odyssey Health, Inc. Successfully Completes Phase I Single Ascending Dosing for Intranasal Concussion Drug
5:33pm
8-K
EX-99.1
1e7vj3k6 itya5b42i
6 May 22
Odyssey Health, Inc. Announces Positive Results from Initial Phase I Clinical Trial Subjects for Concussion Drug
5:15pm
8-K
EX-99.1
wy2c5fr 80
20 Apr 22
Regulation FD Disclosure
5:15pm
8-K
EX-99.1
a6ho056hqpp6gqzd
10 Jan 22
Regulation FD Disclosure
9:02am
8-K
EX-10.1
0sm5v51sy024scw
26 Oct 21
Entry into a Material Definitive Agreement
5:04pm
8-K/A
EX-10.1
qxgzbuwy0llm7cimaxw
26 Oct 21
Entry into a Material Definitive Agreement
4:54pm
8-K
EX-99.1
s06ycba6jdgv8
21 Oct 21
Odyssey Group International Files Patent On Novel Breath-Propelled Nasal Delivery Device
4:20pm
8-K
EX-10.1
mw26i
21 Oct 21
Entry into a Material Definitive Agreement
4:15pm
8-K
EX-99.1
qlu7xlvnz
24 Sep 21
Odyssey Group International Begins Enrolling Subjects for Phase 1 Clinical Trial to Treat Concussion
4:01pm
8-K
EX-99.1
wjh7c2p919kcl
1 Sep 21
Odyssey Group International Approved to Start Human Trial to Treat Concussion
4:15pm
8-K
EX-10.1
42le8ncerehqswod
1 Sep 21
Entry into a Material Definitive Agreement
4:00pm
8-K
EX-99.1
7wdkgkcn3
6 Aug 21
Odyssey Group International Completes IND-enabling Studies, Submits Investigator’s Brochure for Phase 1 Clinical Trial
4:24pm
8-K
EX-10.5
c99510 hft
7 Apr 21
Entry into a Material Definitive Agreement
4:35pm
S-3
qa6lu2wl232zxgte
17 Mar 21
Shelf registration
4:30pm